Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P230030/S024

FARASTAR Pulsed Field Ablation (PFA) Generator; FARASTAR Mapping System Module (MSM); FARASTAR Recording System Modul

Farapulse, Inc. · Decision date Sep 4, 2026

MEDTECHLEDGER EXPLANATIONP230030/S024

What did the FDA approve?

FDA recorded an approval decision on 2026-09-04 for P230030/S024, a real-time process supplement to PMA P230030 held by Farapulse, Inc. The supplement reason is a change in design, components, specifications or material. The recorded statement covers FARASTAR PFA Generator Software 4.5.3/4.6.3, the FARASTAR Foot Switch, and updates to the FARASTAR System Instructions for Use.

The parent filing covers a percutaneous cardiac ablation catheter for atrial fibrillation using irreversible electroporation, in the cardiovascular specialty under product code QZI. This supplement addresses the named software, accessory and labeling items rather than a new approval of the whole system. The source record does not include the decision documents, so the specific technical changes and any conditions of approval remain unknown.

The title field also lists a Mapping System Module and a Recording System Module, but the statement does not describe changes to them, so their status in this supplement is unclear.

FDA approval order statement

approval for FARASTAR PFA Generator Software 4.5.3/4.6.3, FARASTAR Foot Switch, and updates to the FARASTAR System Instructions for Use
Regulatory pathway
PMA supplement
Supplement type
Real-Time Process
Clinical specialty
Cardiovascular
Decision date
Sep 4, 2026
FDA change category
Change Design/Components/Specifications/Material

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P230030/S024
Regulatory pathway
PMA supplement
Product code
QZI
Decision code
APPR
Decision date
Sep 4, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Percutaneous Cardiac Ablation Catheter for Treatment of Atrial Fibrillation with Irreversible Electroporation.

Product code
QZI
FDA device class
3

For the original device and its historical approval scope, see PMA P230030. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P230030 · Original PMA

    FARAPULSE Pulsed Field Ablation System (FARAWAVE Pulsed Field Ablation Catheter, FARASTAR Catheter Connection Cable,

  2. P230030/S024 received

    Application receipt date recorded by FDA.

  3. P230030/S024 · FDA decision

    Real-Time Process

  4. P230030/S025 · Related supplement

    FARAPULSE Pulsed Field Ablation System (FARAWAVE Pulsed Field Ablation Catheter, FARASTAR Catheter Connection Cable,

Timeline entries are records held by MedtechLedger for P230030. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P230030

Explore the linked device profile

Other records with product code QZI

Product / regulatory recordCompanyPathwayDecision dateSource
Biosense Webster, Inc.PMA supplementNov 3, 2026FDA
Kardium, Inc.PMA supplementOct 27, 2026FDA
Kardium, Inc.PMA supplementOct 23, 2026FDA
Volt PFA SystemP250022/S002
ABBOTT MEDICALPMA supplementOct 15, 2026FDA
Medtronic, Inc.PMA supplementOct 9, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Farapulse, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
3715 Haven Ave., Suite 110, Menlo Park, CA, 94025

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records